Sign in
Not yet taking people in United StatesPhase 1

Tests a combined weight loss and quit-smoking program before bariatric surgery

Tests medicines and behavior therapy for weight and smoking in adults seeking surgery.

Key facts

Who runs it
Medical University of South Carolina
Where
Charleston, United StatesSee the site
Trial code
Registry title
Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
Status
Not yet recruiting
Phase
Phase 1
People taking part
20 people, planned
Started
1 Oct 2026
Expected to end
31 Dec 2027
Type of study
Interventional
Treatments tested
  • Naltrexone Hydrochloride
  • Bupropion HCl Extended Release
  • Cognitive-Behavioral Therapy
Record updated
9 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who smoke, have obesity and are thinking about bariatric surgery. It tests a medicine plus behavior therapy for weight loss and quitting smoking.

Age
18 to 65 years old.
Sex
All sexes can join.
Disease stage
BMI of 30.0 kg/m2 or higher. Actively considering bariatric surgery.
Earlier treatment
Must not be taking medicines that interact with Naltrexone or Bupropion (for example opiates, benzodiazepines).
Biomarker or test result
Smoking at least 5 cigarettes daily for the past 3 months.

Main reasons for not taking part

  • History of seizures or a higher risk of seizures
  • History of anorexia nervosa or bulimia nervosa
  • Heart disease, stroke or untreated high blood pressure
  • Pregnant or breastfeeding, or not using reliable birth control
  • Active suicidal or homicidal thoughts

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Be actively considering bariatric surgery
  • Smoke at least 5 cigarettes daily for the past 3 months
  • Have a BMI ≥ 30.0 kg/m2
  • Not currently taking medications that interact with Naltrexone or Bupropion (e.g., opiates, benzodiazepines)
  • No history of medical conditions that are contraindicated with Naltrexone or Bupropion (e.g., seizure disorders, uncontrolled hypertension, cardiac issues including history of heart attacks, heart disease, or stroke, history of anorexia or bulimia nervosa)
  • Physically well enough to participate in the intervention (e.g., able to walk independently)
  • Speak/read/write in English
  • Be 18-65 years old
  • Not currently pregnant or breastfeeding or have plans to become pregnant or breastfeed during the study
  • No active suicidal or homicidal ideation

Who cannot take part

  • Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold)
  • Is currently taking a medication that is contraindicated to Naltrexone or Bupropion (e.g., MAOIs, opiates)
  • Has a history of anorexia nervosa or history of bulimia nervosa
  • Has a history of allergy or sensitivity to Naltrexone or Bupropion
  • Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
  • Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute
  • Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke
  • Has current uncontrolled Type I or Type 2 diabetes mellitus
  • Has a history of severe renal, hepatic, neurological, chronic pulmonary, or gallbladder disease, or any other unstable medical disorder
  • Is breast-feeding or is pregnant or is not using a reliable form of birth control
  • Reports active suicidal or homicidal ideation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Medical University of South CarolinaCharleston, United StatesContact: Caitlin E Smith, PhDNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this research study is to develop and pilot a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior therapy in adults seeking bariatric surgery.

The group in the trial

  • InterventionTreatment being tested

    Participants will receive the multiple health behavior change intervention with combined medication (Naltrexone 50mg/day; Bupropion Extended Release 300mg/day) and behavior therapy (Cognitive-Behavioral Therapy) for 4 months.

    Treatment: Naltrexone Hydrochloride, Bupropion HCl Extended Release, and Cognitive-Behavioral Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Development of a Multiple Health Behavior Change Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
Plain-language title
Tests a combined weight loss and quit-smoking program before bariatric surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07224087, who can take part
Record updated
9 September 2026